The global CNS biomarkers market is projected to reach USD 26.13 billion by 2035, amyloid beta therapeutics USD 26.50 billion, and calcineurin inhibitors USD 20.88 billion. AI integration is driving innovation across all three markets.
The image-guided therapy systems market is expected to grow from US$4.96 billion in 2024 to US$8.42 billion by 2033 at a 6.05% CAGR. Growth is tied to minimally invasive care, chronic disease demand, and advances in imaging, AI, and navigation systems.
Clinical trials take 10-15 years and cost $1-2 billion from discovery to approval, progressing through four phases from safety testing to real-world monitoring. These studies face challenges including high costs, regulatory oversight, and participant recruitment while new technologies are transforming trial design. Illinois faces a shortage of Phase I clinical trial facilities despite local companies conducting over 50 such trials annually.
Creative Biolabs has expanded its preclinical research capabilities with an upgraded rodent behavioral profiling platform for CNS drug discovery and enhanced circRNA and nucleic acid analysis platforms for gene therapy development.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
The global stem cell therapy market is projected to grow from $18.13 billion in 2025 to $59.70 billion by 2035 at a 12.66% CAGR, driven by chronic disease prevalence and regenerative medicine advances.
Multiple analysts have raised price targets on Praxis Precision Medicines, with Wolfe Research initiating coverage at $500 and Guggenheim increasing its target to $800, citing strong market potential for ulixacaltamide in essential tremor.
Researchers at DZNE and the University of Tübingen have identified neurofilament light chain (NfL) as a blood biomarker detectable across animal species, with levels increasing with age and predicting lifespan in mice.
Lunai Bioworks was featured on CNBC on February 13, 2026, showcasing its AI platform for CNS therapeutics and biodefense. The company reported improved financial performance with net income of $1.02 million compared to a $51.46 million loss the previous year.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07539272 |
Device for Driving Simulation for the Rehabilitation of Balance and Proprioception |
NOT_YET_RECRUITING | NA |
| NCT07502937 |
A Multicenter Interventional Study on the Use of a 3-Degree-of-Freedom (3DOF) Platform to Evaluate the Safety and Usability of the System and Its Impact on Balance, Proprioception, and Neurological Deficits in the Rehabilitation of Patients With Neurological Disorders. |
NOT_YET_RECRUITING | NA |
| NCT07477821 |
A Muscle-brain Interplay Study in Neurological Disorders |
RECRUITING | |
| NCT07384143 |
Cognitive Recovery Via Sensor-based Robotic Upper Limb Rehabilitation in Neurological Disorders |
RECRUITING | NA |
| NCT07299344 |
A Model for Continuous Care of Fragile Patients |
NOT_YET_RECRUITING | |
| NCT07268079 |
Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality |
RECRUITING | |
| NCT07131553 |
Evaluation of the Wheelchair School (Drivkraft) a Clinical Study |
NOT_YET_RECRUITING | NA |
| NCT06897553 |
ACT for Mental Health in Neurological Disorders |
RECRUITING | NA |
| NCT06815328 |
Efficacy of Shock Wave Therapy in Post-Stroke Muscle Spasticity Management |
NOT_YET_RECRUITING | NA |
| NCT06668233 |
Neurologocal Symptoms in CHD |
NOT_YET_RECRUITING |
